More MS news articles for Oct 2001

TKT Awarded U.S. Patent Relating to Protein Production and Delivery For Gene Therapy

Tue, Oct 23, 2001, 8:32 AM EDT

CAMBRIDGE, Mass., Oct. 23 /PRNewswire/ -- Transkaryotic Therapies, Inc. (NASDAQ:TKTX) today announced that the U.S. Patent and Trademark Office has issued Patent No. 6,303,379 entitled, "In Vivo Protein Production and Delivery System for Gene Therapy." The patent covers the transfection of cells relating to the delivery of therapeutic proteins. This technology offers several advantages to conventional gene therapy approaches including safety, ease of administration, dose precision, and cost effectiveness.

"The issuance of this patent further strengthens TKT's intellectual property portfolio in the area of non-viral gene therapy," said Mary S. Consalvi, Vice President and Chief Intellectual Property Counsel at TKT. "Utilizing this novel technology, we have the potential to treat a variety of human diseases and conditions, among them anemia, diabetes, hemophilia, hypercholesterolemia, and multiple sclerosis, through the production and delivery of therapeutic proteins."

A copy of the patent described above is available on the World Wide Web at

About TKT

Transkaryotic Therapies, Inc. (TKT) is a biopharmaceutical company dedicated to the development and commercialization of products based on its three proprietary development platforms: Niche Protein(TM) products, Gene- Activated(R) proteins, and Gene Therapy. The Company's Niche Protein product platform is based on protein replacement for the treatment of rare genetic diseases, a group of disorders characterized by the absence of certain metabolic enzymes. TKT's gene activation technology is a proprietary approach to the large-scale production of therapeutic proteins, which does not require the cloning of genes and their subsequent insertion into non-human cell lines. The Company's Gene Therapy technology, known as Transkaryotic Therapy(TM), is focused on the commercialization of non-viral, ex vivo gene therapy products for the long-term treatment of chronic protein deficiency states.

This press release contains forward-looking statements that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward- looking statements. Without limiting the foregoing, the words, "believes," "anticipates," "plans," "expects," "estimates," "intends," "should," "could," "will," "may," and similar expressions are intended to identify forward- looking statements. There are a number of important factors that could cause the Company's actual results to differ materially from those indicated by such forward-looking statements set forth under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2001 which is on file with the Securities and Exchange Commission and incorporated herein by reference. These include, without limitation, the following: (1) whether any of the Company's Niche Protein, Gene-Activated protein or gene therapy product candidates will advance in the clinical trial process, (2) whether such clinical trials will proceed in a timely manner, (3) whether the clinical trial results will warrant continued product development, (4) whether the required regulatory filings, such as Investigational New Drug applications and Biologics License Applications, are made in a timely manner, (5) whether the Company's products will receive approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies, (6) if such products receive approval, whether they will be successfully distributed and marketed, (7) whether patent litigation in which the Company is involved or may become involved are resolved in a manner adverse to the Company, (8) the effects of competitive products on the Company's proposed products, and (9) the Company's dependence on third parties, including collaborators, manufacturers and distributors.

Gene-Activated(R) is a registered trademark and Niche Protein(TM), TKT(TM), and Transkaryotic Therapy(TM) are trademarks of Transkaryotic Therapies, Inc.

Please visit our web site at for additional information about Transkaryotic Therapies, Inc.

Daniel E. Geffken
Senior Vice President, Finance
and Chief Financial Officer
(617) 349-0581

©2001 At Home Corporation